

20. A compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use as a CK1 delta or CK1 epsilon activity inhibitor.

21. Use of an inhibitor of CK1 delta or CK1 epsilon, wherein the inhibitor is a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a mood disorder or a sleep disorder.

~~22. The use according to claim 21 wherein said inhibition of CK1 delta or CK1 epsilon activity results in a lengthening of the circadian rhythm period.~~

~~23~~22. The use according to claim ~~22~~21 wherein the sleep disorder is a circadian rhythm sleep disorder that is selected from the group consisting of shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome and delayed sleep phase syndrome; and the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

~~24~~23. The compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for use in the treatment of a neurological and psychiatric disease or disorder.

~~25~~24. Use of a compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a neurological or psychiatric disorder that is selected from the group consisting of cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia, AIDS-induced dementia, vascular dementia, mixed dementias, age-associated memory impairment, Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, including cognitive disorders associated with schizophrenia and bipolar disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, migraine, migraine headache, urinary incontinence, substance tolerance, substance withdrawal, withdrawal from opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, and hypnotics, psychosis, mild cognitive impairment, amnesic cognitive impairment, multi-domain cognitive impairment, obesity, schizophrenia, anxiety, generalized anxiety disorder, social

anxiety disorder, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, mood disorders, depression, mania, bipolar disorders, trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain, acute and chronic pain states, severe pain, intractable pain, neuropathic pain, post-traumatic pain, tardive dyskinesia, sleep disorders, narcolepsy, attention deficit/hyperactivity disorder, autism, Asperger's disease, and conduct disorder.

| 2625. The use according to claim 2423 wherein the disease or disorder is a mood disorder or a sleep disorder.

| 2726. The use according to claim 2524 –wherein the disease or disorder is a mood disorder or a sleep disorder.

| 2827. The use according to claim 2625 -wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

| 2928. The use according to claim 2726 wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder.

| 3029. A pharmaceutical composition comprising a compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.